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Abstract 99 
Allogeneic haemopoietic cell transplant (allo-HCT) may 100 
be curative in acute myeloid leukaemia (AML) in second 101 
complete remission (CR2) but the impact of reduced 102 
intensity (RIC) versus myeloablative conditioning (MAC) 103 
is uncertain. The Acute Leukaemia Working Party of the 104 
European Society for Blood and Bone Marrow 105 
Transplantation Registry studied an AML CR2 cohort 106 
characterised by age ≥18y, first allo-HCT 2007-2016, 107 
available cytogenetic profile at diagnosis, donors who 108 
were matched family, volunteer unrelated with HLA 109 
antigen match 10/10 or 9/10 or haplo-identical. The 1879 110 
eligible patients included 1010 (54%) MAC allo-HCT 111 
recipients.  112 
 113 
In patients <50 years (y), two year outcomes for MAC vs 114 
RIC allo-HCT were equivalent with leukaemia free 115 
survival (LFS) 54% for each, overall survival (OS), 61 vs 116 
62%, non-relapse mortality (NRM) 18 vs 15% and graft 117 
versus host disease relapse free survival (GRFS) 38 vs 118 
42%. In patients ≥50y, 2y outcomes for MAC vs RIC allo-119 
HCT were equivalent for LFS 52 vs 49%, OS 58 vs 55% 120 
and GRFS 42.4 vs 36%. However, NRM was significantly 121 
inferior after MAC allo-HCT, 27 vs 19% (P=0.01) despite 122 
worse cGVHD after RIC-allo (32 vs 39%). These data 123 
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support the need for ongoing prospective study of 124 
conditioning intensity and GVHD mitigation in AML. 125 
 126 
FUNDING: This study was supported by the European 127 
Society for Blood and Bone Marrow Transplantation 128 
funded by annual subscription from the constituent 129 
transplant centres. 130 
 131 
Introduction 132 
Acute myeloid leukaemia (AML) is grouped into good, 133 
intermediate and adverse genetic risk categories that 134 
may be combined with response rates to induction 135 
therapy to predict survival outcomes (1–3). Integration of 136 
relapse rates, procedural mortality of allogeneic 137 
haemopoietic cell transplant (allo-HCT) and projected 138 
success rates of salvage regimens permits an estimate of 139 
the potential benefit and optimal timing of an allo-HCT as 140 
consolidation therapy (4–6,1). Consequently, for patients 141 
achieving first complete remission (CR1) it is 142 
conventional to offer allo-HCT in adverse and 143 
intermediate risk disease where the relapse risk is more 144 
than 45% and there are clear benefits to transplantation 145 
(7,8). Allo-HCT is deferred to CR2 for patients with good 146 
risk disease despite a relapse risk of up to 35%, since 147 
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many will be cured without the hazards of allo-HCT (5). 148 
However, management of an individual patient requires a 149 
personalised amalgamation of risk of relapse, transplant 150 
related mortality and access to a suitable donor 151 
(1,6,9,10). Thus, patients with high HCT comorbidity 152 
index scores and a mismatched volunteer donor may 153 
wish to defer allo-HCT (11,12).   154 
 155 
While it is often assumed that those patients who relapse 156 
subsequent to a first CR may be duly salvaged and 157 
offered allo-HCT in CR2, this does not square with reality 158 
(13–16). Breems et al studied a cohort of 1540 patients 159 
with newly diagnosed AML enrolled on clinical trials 160 
between 1987 and 2001 and established that the duration 161 
of CR1, age at relapse, cytogenetic risk factor at 162 
diagnosis and a prior allo-HCT could be used to predict 163 
the likelihood of CR2 (4). Those patients who did achieve 164 
CR2 were shown to have a survival benefit from allo-HCT 165 
compared to alternative therapies.  Subsequent studies 166 
have largely confirmed these findings (Table 1)  (17–21). 167 
 168 
Since no other large series address the impact of 169 
conditioning regimen intensity on the outcomes of HCT in 170 
patients with AML CR2, we have analysed an eligible 171 
cohort of patients for whom data had been deposited in 172 
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the registry of the European Society for Blood and 173 
Marrow Transplantation (EBMT).  174 
 175 
Methods 176 
Study design and data collection  177 
This was a multicentre, retrospective registry study by the 178 
Acute Leukaemia Working Party (ALWP) of the EBMT. 179 
The EBMT is a voluntary group that represents more than 180 
600 transplant centers, predominantly European, which 181 
are required to report all consecutive HCT and follow-up 182 
once a year. EBMT Med A/B standardized data collection 183 
forms are completed and submitted to the registry by 184 
transplant center personnel following written informed 185 
consent from patients in accordance with center ethical 186 
research guidelines (22). Accuracy of data is assured by 187 
the individual transplant centers and by quality control 188 
measures such as regular internal and external audits.  189 
Since January 1, 2003, all transplant centers have been 190 
required to obtain written informed consent prior to data 191 
registration with the EBMT, following the Helsinki 192 
Declaration of 1975.The study was approved by the 193 
ALWP. 194 
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Eligibility criteria  195 
Eligibility criteria were: age ≥18y, first allo-HCT 2007-196 
2016, diagnosis of AML CR2, availability of cytogenetic 197 
profile at diagnosis.   198 
Cytogenetic status was classified using MRC UK criteria 199 
while any identified molecular markers at diagnosis were 200 
also noted (23). Donors were restricted to a human 201 
leukocyte antigen (HLA) matched family donor (MFD), 202 
volunteer unrelated donor with HLA match 10/10 (VUD) 203 
or 9/10 match (MMVUD) or haplo-identical (Haplo ID) 204 
donor. Graft source included peripheral blood stem cells 205 
(PBSC) or bone marrow (BM) grafts. Engraftment was 206 
assessed by conventional EBMT standards (22). 207 
 208 
Intensity of conditioning was classified in accordance with 209 
published criteria while the more recently adopted 210 
regimens Treosulfan/Fludarabine (TF) and 211 
Thiotepa/Busulfan/Fludarabine (TBF) were considered as 212 
myeloablative when the busulfan dose was at least 9.6 213 
mg/kg (24–26). 214 
Statistical analysis 215 
Patient, disease, and transplant-related characteristics for 216 
the two cohorts (MAC or RIC) were compared by using χ2 217 
statistics for categorical variables and the Mann-Whitney 218 
test for continuous variables. The primary endpoint was 219 
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leukemia-free survival (LFS). Secondary endpoints were 220 
relapse incidence (RI), non-relapse mortality (NRM), 221 
overall survival (OS), acute graft-versus-host disease 222 
(aGVHD), chronic graft-versus-host-disease (cGVHD) 223 
and GVHD-free/relapse-free survival (GRFS). LFS was 224 
defined as survival with no evidence of relapse or 225 
progression. Relapse was defined as the presence of 5% 226 
BM blasts and/or reappearance of the underlying 227 
disease. NRM was defined as death without evidence of 228 
relapse or progression. OS was defined as the time from 229 
allo-HCT to death, regardless of the cause. GRFS was 230 
defined as events excluding grade 3-4 acute GVHD, 231 
extensive chronic GVHD, relapse, or death in the first 232 
post-HCT year (27–29). 233 
 234 
Cumulative incidence was used to estimate the endpoints 235 
of NRM, RI, acute and chronic GVHD to accommodate 236 
for competing risks. To study acute and chronic GVHD, 237 
we considered relapse and death to be competing 238 
events. Probabilities of OS, LFS, and GRFS were 239 
calculated using the Kaplan–Meier method. Univariate 240 
analyses were done using the Gray’s test for cumulative 241 
incidence functions and the log rank test for OS, GRFS, 242 
and LFS.  Cox proportional hazards model was used for 243 
multivariate regression. All variables differing significantly 244 
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between the 2 groups or factors associated with one 245 
outcome in univariate analysis were included in the Cox 246 
model. In order to test for a centre effect, we introduced a 247 
random effect or frailty for each center into the model 248 
(30,31). We studied 2 different Cox models in patients 249 
aged under 50 or 50 years and above at the time of allo-250 
HCT. Results were expressed as the hazard ratio (HR) 251 
with a 95% confidence interval (95% CI). Proportional 252 
hazards assumptions were checked systematically for all 253 
proposed models using the Grambsch-Therneau 254 
residual-based test. All tests were 2-sided. The type I 255 
error rate was fixed at 0.05 for the determination of 256 
factors associated with time-to-event outcomes. Analyses 257 
were stratified by age at allo-HCT (less or >50 years) and 258 
declared measurable residual disease (MRD) status at 259 
HCT. Statistical analyses were performed with SPSS 260 
24.0 (SPSS Inc., Chicago, IL, USA) and R 3.4.0 (R Core 261 
Team (2017). R: A language and environment for 262 
statistical computing. R Foundation for Statistical 263 
Computing; Vienna; Austria. https://www.R-project.org/.)   264 
 265 
Results 266 
Patient, disease and transplant characteristics 267 
A total of 1879 patients, 1013 male, from 230 transplant 268 
centers were eligible. Patient, disease, donor and 269 
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transplant characteristics are detailed in Supplementary 270 
Table 1 (Table S1).  271 
Median follow-up of surviving patients was 26.16 months 272 
(m) (0.49 - 124.63). Approximately 95% of patients in 273 
each group had de novo AML at initial diagnosis. 274 
MAC regimens were used in 1010 while 869 received 275 
RIC allo-HCT. Time from diagnosis to transplant was 276 
marginally longer in RIC allo-HCT recipients at a median 277 
of 18.5 m (range 0.8-222.9) vs 17.7m (1.2-239.1) 278 
(P=0.017) in MAC recipients.   279 
Recipients of RIC allo-HCT compared to MAC allo-HCT 280 
recipients were older (median age 57.3y (18.2-75.3) vs 281 
42.8y, (18-72y) P<0.001), had a worse Karnofsky 282 
performance status (P<0.001) and had a higher 283 
proportion of adverse or intermediate cytogenetics at 284 
diagnosis (P <10-3) (Table S1).  285 
Family donors, whether MFD or Haplo-ID, were more 286 
commonly available for MAC allo-HCT than RIC allo-HCT 287 
recipients and accounted for half of the donors in the 288 
MAC allo-HCT group. Conversely, unrelated donors, 289 
particularly HLA 10/10 VUDs were more likely than family 290 
donors to be used in the RIC allo-HCT setting (P<0.0 01). 291 
While PBSC was the preferred source of stem cells in 292 
both conditioning groups, this was more pronounced in 293 
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the RIC allo-HCT group with only 7.59% cases using BM 294 
vs 24.78% in the MAC HCT group (P<0.001). A 295 
preference for male donors was seen in both groups and 296 
particularly so in RIC allo-HCT (P=0.005) (Table S1). 297 
Transplant characteristics are shown in Table S1. T cell 298 
depletion, whether with anti-thymocyte globulin or 299 
alemtuzumab was applied in 47.01% MAC HCT and 300 
70.59% RIC/NMA HCT (P <0.001). 301 
Regimens used for GVHD prophylaxis favoured 302 
cyclosporine based approaches rather than tacrolimus or 303 
post-transplant cyclophosphamide. Cyclosporine was 304 
most often used in combination with methotrexate in MAC 305 
HCT and alone or with mycophenolate mofetil in 306 
RIC/NMA HCT (P<0.001). 307 
  308 
Outcomes of transplantation 309 
At 2y, the overall outcomes were LFS 52% (CI: 49.5 - 310 
54.5), OS 58.7% (CI: 56.2 - 61.2), RI 28.9% (CI: 26.7 - 311 
31.2), NRM 19% (CI: 17.2 - 21), GRFS 38.7% (CI: 36.2 - 312 
41.1), cGVHD 37.2% (CI: 34.7 - 39.7) and extensive 313 
cGVHD 15.9% (CI: 14.1 - 17.8) (Tables S2 and S3) Non-314 
relapse deaths were predominantly due to GVHD or 315 
sepsis (Table S2). 316 
 317 
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Multivariate analysis was performed to examine the 318 
impact of conditioning intensity as well as other 319 
parameters believed to determine transplant outcomes. 320 
Table S4 summarises the MVA for all patients. In this 321 
cohort, no transplant outcome differed significantly by 322 
conditioning intensity with the notable exception of NRM 323 
which favoured RIC Allo-HCT, (HR 0.65 95% CI 0.50-324 
0.84 P=0.001). However, when patients were divided by 325 
age range <50y vs ≥50y this advantage to RIC ALLO-326 
HCT retained significance only in patients ≥50y (HR 0.54 327 
CI 0.38-0.76 P <0.001) (Tables 2 and 3). Thus, even in 328 
patients selected as being fit for MAC Allo-HCT by their 329 
transplant team, we found excess NRM in older patients. 330 
This is supported by the increase in NRM that is seen 331 
with increasing age in the <50y (HR 1.25 CI 1.01-1.53 332 
P=0.034) as well as the ≥50y (HR 1.6 CI: 1.21-2.03 333 
P=0.001) (Tables 2 and 3). 334 
 335 
The other striking association with conditioning intensity 336 
was also seen in patients ≥50y, but not in younger 337 
patients, and this was an excess of cGVHD in those 338 
undergoing RIC allo-HCT (HR 1.38 CI 1.03-1.85; P=0.03) 339 
although this difference did not extend to extensive 340 
GVHD (Table 3).   341 
 342 
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A decision to use reduced intensity rather than 343 
myeloablative conditioning may be influenced by the age, 344 
comorbidity and performance status of the patient (32–345 
34). As well as the impact of increasing age as a 346 
continuous variable on NRM, we also found an adverse 347 
effect on GRFS which reached significance in patients 348 
<50y (HR 1.13 CI 1.01-1.26 P=0.03) while remaining a 349 
trend in older patients. Overall, older patients also had 350 
worse LFS and OS (31–(32–34)33) (Table S4 and Table 351 
3).  352 
 353 
Karnofsky Performance Scores (KPS) >80% were 354 
predictive of lower NRM in both age-groups. Additionally, 355 
in patients ≥50y, KPS >80 predicted lower rates of 356 
aGVHD and superior OS, LFS and GRFS (Table 3).  357 
In accordance with other large studies of patients 358 
transplanted in AML CR2 that  have found better 359 
transplant outcomes in those patients with longer duration 360 
CR1, probably reflecting the innate aggressiveness of 361 
disease, (17–20), we found that patients with longer 362 
intervals from diagnosis to allo-HCT had superior RI, 363 
LFS, OS and GRFS.  (Table S4). 364 
 365 
The distribution of cytogenetic risk groups at diagnosis 366 
resembled the MRC and Japanese cohorts (17,18). 367 
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Patients with good risk cytogenetics at diagnosis fare 368 
better after transplant than those with intermediate and 369 
adverse risk cytogenetics (17–20) and our results are 370 
confirmatory in a different data set and across all age 371 
groups. (Supplementary Tables 4 and 5).  372 
At 2y, OS following allo-HCT was 67.4, 56.8 and 37.9% in 373 
good, intermediate and adverse risk cytogenetic groups 374 
respectively. Overall, this compares favourably with the 375 
5y OS of 35, 47 and 34% reported by Burnett in which 376 
survival curves flattened between 2 and 3 years from 377 
transplant, but emphasises the persistently poor outcome 378 
due to relapse for patients with adverse karyotypes 379 
(17,32,35,36). 380 
 381 
Donor selection has historically had a major impact on 382 
the outcomes of transplant, although the increasing use 383 
of high resolution HLA typing and novel GVHD 384 
prophylaxis strategies may be eroding the differences in 385 
outcomes associated with unrelated versus matched or 386 
haploidentical family donors  (37–40). In this study we 387 
found that donor characteristics retained a significant 388 
impact upon transplant outcomes (Tables 2 and 3). 389 
MMVUD and Haplo-ID donors were associated with 390 
increased rates of NRM and aGVHD II-IV and the use of 391 
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female donors was associated with higher rates of 392 
extensive cGVHD.  393 
In general in modern transplant practice PBSC is the 394 
preferred stem cell source although faster engraftment 395 
may be offset by increased risks of GVHD (41). We found 396 
that the use of PBSC was associated with significantly 397 
increased rates of cGVHD in both the <50y and the ≥50y 398 
(HR 1.784 CI 1.253-2.539, HR 1.683 CI 1.08-2.624) but 399 
no improvements in OS or LFS in either group (Tables 2 400 
and 3). Similar to our earlier study in AML CR1, (42), 401 
TCD led to beneficial effects on GRFS, aGVHD and 402 
cGVHD in <50y and to improvements in GRFS and 403 
cGVHD in the ≥50y without detriment to RI, OS or LFS 404 
suggesting that TCD reduces GVHD without increasing 405 
relapse risks (Tables 2 and 3).   406 
 407 
Finally, we looked for the impact of centre and year of 408 
transplant but found no significant effect on transplant 409 
outcomes (Tables 3 and 4). 410 
 411 
Discussion  412 
 413 
This large registry study tracked the effect of allo-HCT on 414 
the post-transplant survival characteristics of 1879 415 
patients with AML in CR2 in the modern era (2007-2016) 416 
and investigated the impact of conditioning intensity on 417 
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outcomes in patients aged <50y or ≥50y. OS, LFS and 418 
GRFS at 2y were 58.7%, 52% and 38.7%.  419 
We established that in patients aged <50y, 2y OS was 420 
61.1% vs 61.8% for MAC vs RIC allo-HCT (P=0.7) while 421 
LFS was 53.9% vs 54.1% (P=0.61). Similarly, in patients 422 
aged 50y or more at HCT, MAC allo-HCT and RIC allo-423 
HCT were equivalent with 2y OS of 58.3% vs 55.1% 424 
(P=0.3) and LFS of 51.5% vs 49.3% (P=0.7). Multivariate 425 
analysis confirmed that in patients <50y and ≥50y, 426 
intensity of conditioning made no significant difference to 427 
OS, LFS or RI. However, in ≥50y, NRM rates were 428 
significantly reduced following RIC allo-HCT and while 429 
there was an increased risk of cGVHD this did not 430 
manifest as extensive cGVHD. These observations 431 
suggest overall equivalence of MAC and RIC regimens 432 
and a rationale for further prospective study. This is in 433 
keeping with our previous observations in AML CR1 but 434 
contrasts with the outcomes of the Blood and Marrow 435 
Transplant Clinical Trials Network (BMT CTN) 0901 436 
prospective study of 272 patients with AML or 437 
myelodysplasia in which high relapse rates in patients 438 
receiving RIC Allo-HCT compared to MAC Allo-HCT led 439 
to premature study closure (42,43). Despite the caveat 440 
that our current study is retrospective, it is a larger one, 441 
encompassing a wider range of regimens and with longer 442 
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follow-up. Additionally, the outcomes of patients with AML 443 
CR2 in the BMT CTN study are not specified.   444 
 445 
Similar to earlier studies, we found that adverse factors 446 
included increasing age, cytogenetics other than good 447 
risk, poor performance status, shorter time intervals from 448 
initial diagnosis to transplant and mismatched donor allo-449 
HCT (4,17,20).  450 
 451 
Given the high rates of relapse, with overall 2y RI of 452 
28.9%, there is a grave need for more active leukaemia 453 
therapy. This might be addressed by sequential 454 
chemotherapy approaches such as the FLAMSA based 455 
regimens or by combining alkylating agents in the 456 
conditioning regimen (26,44–46). Additionally, new agents 457 
hold out the promise of higher CR rates and prospects for 458 
maintenance therapies which may potentially be used in 459 
conjunction with allo-HCT to improve survival in AML(47–460 
50). Immunotherapy approaches, while less advanced 461 
than for lymphoid malignancies also hold potential (51). 462 
 463 
Our study is limited since it can only address the 464 
outcomes of those patients who achieved CR2 and were 465 
transplanted, thus not addressing the larger problem of 466 
management of relapse after CR1. Likewise, we may only 467 
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speculate as to the reasons why allo-HCT was deferred 468 
to CR2. We had insufficient data to draw conclusions 469 
about the impact of comorbidity, MRD or molecular sub-470 
groups such as FLT3 ITD with or without NPM1 471 
mutations (34,52–54). While MRD status was available in 472 
67% patients, equally distributed across conditioning 473 
groups, it had no confounding influence on the 474 
relationship between conditioning intensity and transplant 475 
outcomes.  476 
 477 
However, we show improving survival outcomes after 478 
allo-HCT in a large cohort of patients with AML CR2 479 
treated in a recent time-frame while confirming that 480 
existing prognostic indicators retain their value. These 481 
data also provide fresh impetus for the prospective 482 
comparison of the impact of conditioning intensity on allo-483 
HCT outcomes in AML CR2. 484 
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Legends 764 
Main text tables 765 
Table 1 Large Studies of outcome of haemopoietic cell 766 
transplant in second complete remission 767 
 768 
Table 2 Multivariate analysis of outcomes of haemopoietic 769 
cell transplant in patients aged under 50 years. 770 
aGVHD acute graft versus host disease 771 
Allo-HCT allogeneic hematopoietic cell transplant 772 
AML acute myeloid leukemia 773 
cGVHD chronic graft versus host disease 774 
CI confidence interval 775 
GRFS graft versus host disease and relapse free survival 776 
Haplo haploidentical 777 
HR hazard ratio 778 
KPS Karnofsky performance status 779 
LFS Leukaemia free survival 780 
MFD matched family donor 781 
MMVUD mismatched volunteer unrelated donor 782 
NRM Non-relapse mortality 783 
OS Overall survival 784 
PBSC peripheral blood stem cells 785 
RI relapse incidence 786 
TCD T cell depletion 787 
VUD volunteer unrelated donor 788 
 789 
Table 3 Multivariate analysis of outcomes of haemopoietic 790 
cell transplant in patients aged 50 years or above. 791 
aGVHD acute graft versus host disease 792 
Allo-HCT allogeneic hematopoietic cell transplant 793 
AML acute myeloid leukemia 794 
cGVHD chronic graft versus host disease 795 
CI confidence interval 796 
GRFS graft versus host disease and relapse free survival 797 
Haplo haploidentical 798 
HR hazard ratio 799 
KPS Karnofsky performance status 800 
LFS Leukaemia free survival 801 
MFD matched family donor 802 
MMVUD mismatched volunteer unrelated donor 803 
NRM Non-relapse mortality 804 
OS Overall survival 805 
PBSC peripheral blood stem cells 806 
RI relapse incidence 807 
TCD T cell depletion 808 
VUD volunteer unrelated donor 809 
 810 
 811 
Allograft in second remission acute myeloid 
leukaemia… 
 
29 
 
 812 
Figure 1 813 
Outcomes of reduced intensity conditioning (RIC) versus 814 
myeloablative conditioning (MAC) allogeneic 815 
haemopoietic cell transplant in patients aged 50 or older. 816 
(a) Non-relapse mortality (NRM) 817 
(b) Relapse incidence 818 
(c) Chronic Graft versus Host disease  819 
(d) Overall survival (OS) 820 
(e) Leukaemia-free survival (LFS) 821 
(f) Graft versus host and relapse free survival (GRFS) 822 
 823 
Table 1
Author, Group & Study type Study population Outcomes Conclusions and limitations
Burnet et al (reference 17)
UK Medical Research Council
n=1160
Age 16-49y
AML patients in first relapse (excluding APL 
and any prior transplant)
Risk stratification by MRC criteria (Grimwade 
et al 2001 reference 23)
Era: 1988-2009
642 (55%) achieved CR2.
314 (27%) had allo-HCT
Allo-HCT 5Y OS from CR2 by MRC risk category:  
Good: 35% overall, t(8;21) 29% and inv16 39%
Intermediate: 47%
Adverse: 34%
Unknown: 53%
Post-trial analysis with centre defined relapse and reinduction.
The benefits of allo-HCT were seen only in those with intermediate or 
adverse cytogenetic risk groups at diagnosis. 
Multivariate analysis found that only  CR1 duration was significantly 
associated with survival. 
Conditioning intensity did not determine outcome. 
Era coincides with significant changes in HCT practice such as the 
introduction of reduced intensity conditioning and improvements in 
supportive care and high resolution HLA typing.
Kurosawa et al(reference 18)
Japan retrospectivenational study,
n=931
Age 16-70y
AML patients in first relapse (excluding APL 
and any with prior transplant)
Risk stratification by South-West Oncology 
Group (SWOG) criteria(reference 21).
Era 1994-2006
463 (50%) achieved CR2
242 (26%) had allo-HCT in CR2
Allo-HCT 3Y OS from relapse by SWOG cytogenetic risk criteria
Overall: 59%
Good: t(8;21) 64% and inv16 70%
Intermediate: 58%
Adverse:67%
The benefits of allo-HCT were only seen in those with intermediate or 
adverse risk cytogenetic risk groups at diagnosis. 
Multivariate analysis found that CR1 duration ≥1y, cytogenetic risk group at 
diagnosis, white cell count at diagnosis ≤20 x109/L and CR1 status achieved 
with first cycle of inducton therapy all predicted survival after relapse.
Era coincides with significant changes in HCT practice such as the 
introduction of reduced intensity conditioning and improvements in 
supportive care and high resolution HLA typing.
Hospital et al,(reference 19)
French AML Intergroup retrospective 
study 
n=145
Age 16-76y
AML patients with core-binding factor 
mutations in first relapse (excluding any with 
prior transplant).
Era 1994-2011
127 (88%) achieved CR2
77 (53%) had allo-HCT in CR2
Allo-HCT 5Y OS 59% and DFS 57% from relapse
Incorporation of gemtuzumab ozogamycin (GO) into salvage 
regimen yielded superior 5Y OS of 82 vs 48% and DFS of 83 vs 44%.
Multivariate analysis found that the benefits of allo-HCT were greater in 
younger patients, those with inv16/t(16;16), longer duration CR1 and use of 
GO as part of salvage therapy at relapse.
Era spans 17 years during which confounders such as experience of RIC-Allo-
HCT, supportive care and resolution of HLA matching made significant 
advances. 
Residual disease status by molecular and/or immunophenotype was 
unavailable.
Weisdorf et al(reference 20)
Center for International Blood Marrow 
Transplant Research retrospective study
n=4682
Age ≥ 18y
AML patients with disease status primary 
induction failure (PIF) n=1440, median age 
52y, relapse failing ≥1 reinduction cycle (RI) n 
=1256, median age 49y and CR2 n = 
1986,median age 47y.
All patients received an allo-HCT
Era 2000-2013
Allo-HCT 5Y OS:
PIF 21%,
RI 18%
CR2 39%  
Multivariate analysis found that the superior outcomes of allo-HCT in AML 
CR2 were associated with better performance scores (≥90), longer duration 
CR1 (>12 months), a history of de novo  AML and non-adverse cytogenetics 
(SWOG criteria).
Era spans 13 years during which confounders such as experience of RIC-Allo-
HCT, supportive care and resolution of HLA matching made significant 
advances. 
Residual disease status by molecular and/or immunophenotype was 
unavailable.
Table 2
HR CI p HR CI p HR CI p
Age <50y
RIC vs MAC 1.00 0.724 - 1.38 1.00 0.779 0.513 - 1.182 0.24 0.903 0.7 - 1.166 0.43
Age (per 10 y) 1.05 0.898 - 1.219 0.56 1.245 1.014 - 1.529 0.04 1.114 0.986 - 1.259 0.08
Time Diagnosis to allo-HCT (m) 0.96 0.948 - 0.975 <10-5 0.999 0.991 - 1.007 0.78 0.982 0.974 - 0.99 10-5
Cytogenetics
   Good risk group (reference data 1.00 1.00 1.00
   Intermediate 1.52 1.115 - 2.071 0.01 0.922 0.638 - 1.331 0.66 1.266 1.001 - 1.603 0.05
   Adverse 3.347 2.26 - 4.958 <10-5 0.917 0.463 - 1.816 0.80 2.326 1.675 - 3.23 <10-5
Donor 
   MFD (reference data) 1.00 1.00 1.00
   VUD 10/10 0.809 0.578 - 1.131 0.21 1.271 0.802 - 2.014 0.31 0.97 0.74 - 1.27 0.82
   MMUD 9/10 0.842 0.546 - 1.3 0.44 1.986 1.168 - 3.377 0.01 1.189 0.854 - 1.657 0.31
   Haplo 0.576 0.312 - 1.065 0.08 2.096 1.097 - 4.002 0.02 0.944 0.61 - 1.462 0.80
KPS>80% 1.084 0.497 - 2.362 0.84 0.447 0.219 - 0.914 0.03 0.716 0.424 - 1.207 0.21
PBSC vs BM 0.714 0.51 - 0.999 0.05 1.599 0.97 - 2.636 0.07 0.957 0.725 - 1.264 0.76
Year of allo-HCT 1.005 0.953 - 1.06 0.86 0.987 0.922 - 1.057 0.72 1.002 0.961 - 1.045 0.93
Patient female 0.865 0.659 - 1.135 0.29 0.981 0.693 - 1.389 0.92 0.894 0.723 - 1.107 0.31
Donor female 0.76 0.574 - 1.006 0.06 1.089 0.77 - 1.539 0.63 0.87 0.701 - 1.081 0.21
in vivo TCD 1.064 0.767 - 1.475 0.71 0.853 0.564 - 1.289 0.45 0.972 0.752 - 1.256 0.83
centre 0.25 0.25 0.18
HR CI p HR CI p HR CI p
Age <50y
RIC vs MAC 0.914 0.7 - 1.192 0.507 0.863 0.683 - 1.091 0.217 0.863 0.62 - 1.201 0.381
Age (per 10 y) 1 0.965 - 1.25 0.155 1.129 1.012 - 1.259 0.030 1.017 0.869 - 1.189 0.838
Time Diagnosis to allo-HCT (m) 0.982 0.974 - 0.991 <10-4 0.991 0.985 - 0.997 0.003 0.999 0.992 - 1.006 0.763
Cytogenetics
   Good risk group (reference data 1 1 1
   Intermediate 1.318 1.026 - 1.692 0.031 1.14 0.926 - 1.403 0.217 0.91 0.678 - 1.222 0.531
   Adverse 2.417 1.708 - 3.421 <10-5 1.822 1.344 - 2.471 <10-3 0.804 0.484 - 1.337 0.401
Donor 
   MFD (reference data) 1 1 1
   VUD 10/10 1.044 0.784 - 1.389 0.770 1.049 0.825 - 1.334 0.698 2.057 1.439 - 2.939 <10-4
   MMUD 9/10 1.406 0.997 - 1.983 0.052 1.195 0.881 - 1.622 0.252 2.679 1.721 - 4.17 <10-4
   Haplo 1.217 0.776 - 1.908 0.393 0.692 0.46 - 1.039 0.076 1.595 0.949 - 2.683 0.078
KPS>80% 0.62 0.371 - 1.035 0.067 0.955 0.574 - 1.588 0.859 0.701 0.356 - 1.378 0.303
PBSC vs BM 1.087 0.809 - 1.46 0.581 1.252 0.97 - 1.615 0.084 1.203 0.849 - 1.705 0.298
Year of allo-HCT 0.989 0.946 - 1.035 0.643 1.021 0.983 - 1.06 0.288 0.974 0.927 - 1.023 0.291
Patient female 0.838 0.667 - 1.053 0.129 0.917 0.758 - 1.109 0.371 0.88 0.668 - 1.161 0.367
Donor female 0.941 0.749 - 1.183 0.603 0.953 0.787 - 1.154 0.623 0.811 0.613 - 1.074 0.144
in vivo TCD 0.901 0.692 - 1.173 0.439 0.622 0.492 - 0.786 <10-4 0.479 0.346 - 0.663 <10-4
centre 0.291 0.090 0.912
HR CI p HR CI p HR CI p
Age <50y
RIC vs MAC 0.773 0.414 - 1.443 0.418 0.959 0.698 - 1.317 0.795 1.024 0.638 - 1.644 0.922
Age (per 10 y) 1.129 0.841 - 1.515 0.418 1.049 0.907 - 1.213 0.519 0.999 0.803 - 1.242 0.993
Time Diagnosis to allo-HCT (m) 1.004 0.993 - 1.014 0.499 1.005 1 - 1.011 0.067 0.997 0.988 - 1.007 0.564
Cytogenetics
   Good risk group (reference data 1 1 1
   Intermediate 1.011 0.589 - 1.735 0.969 1.011 0.77 - 1.328 0.936 0.904 0.604 - 1.351 0.621
   Adverse 1.03 0.423 - 2.506 0.949 1.354 0.846 - 2.167 0.206 1.187 0.564 - 2.495 0.652
Donor 
   MFD (reference data) 1 1 1
   VUD 10/10 1.844 1.002 - 3.395 0.049 1.205 0.879 - 1.652 0.247 1.27 0.816 - 1.977 0.290
   MMUD 9/10 1.529 0.657 - 3.559 0.324 1.072 0.689 - 1.669 0.758 0.963 0.481 - 1.926 0.914
   Haplo 0.881 0.29 - 2.672 0.823 0.771 0.446 - 1.332 0.351 0.501 0.199 - 1.264 0.143
KPS>80% 0.477 0.169 - 1.345 0.162 1.608 0.633 - 4.083 0.318 4.276 0.563 - 32.455 0.160
PBSC vs BM 1.504 0.765 - 2.958 0.237 1.784 1.253 - 2.539 0.001 3.131 1.738 - 5.64 <10-3
Year of allo-HCT 0.971 0.886 - 1.064 0.528 0.974 0.924 - 1.026 0.315 1.052 0.971 - 1.14 0.213
Patient female 0.821 0.492 - 1.369 0.450 1.04 0.802 - 1.348 0.768 0.849 0.578 - 1.247 0.404
Donor female 0.825 0.493 - 1.381 0.465 1.719 1.331 - 2.22 <10-4 1.515 1.047 - 2.194 0.028
in vivo TCD 0.429 0.24 - 0.769 0.004 0.562 0.411 - 0.77 <10-3 0.27 0.167 - 0.435 <10-5
centre 0.779 0.076 0.016
acute GVHD III-IV chronic GVHD ext. chronic GVHD
Relapse NRM LFS
OS GRFS acute GVHD II-IV
Table 3
HR CI p HR CI p HR CI p
Age ≥50y
RIC vs MAC 1.261 0.912 - 1.743 0.161 0.535 0.378 - 0.758 <10-3 0.883 0.695 - 1.122 0.310
Age (per 10 y) 0.981 0.781 - 1.232 0.868 1.567 1.211 - 2.027 0.001 1.205 1.013 - 1.432 0.035
Secondary AML 0.857 0.521 - 1.41 0.543 0.99 0.564 - 1.737 0.971 0.916 0.63 - 1.333 0.647
Time Diagnosis to allo-HCT (m) 0.974 0.963 - 0.986 10-5 1.001 0.992 - 1.01 0.786 0.987 0.98 - 0.995 0.001
Cytogenetics
Good risk group (reference data) 1 1 1
   Intermediate 1.436 1.006 - 2.049 0.046 0.869 0.585 - 1.292 0.488 1.163 0.892 - 1.518 0.265
   Adverse 1.79 1.035 - 3.096 0.037 1.108 0.579 - 2.121 0.756 1.465 0.961 - 2.234 0.076
Donor 
   MFD (reference data) 1 1 1
   VUD 10/10 1.097 0.805 - 1.495 0.558 1.237 0.822 - 1.859 0.308 1.146 0.894 - 1.469 0.281
   MMUD 9/10 0.93 0.614 - 1.409 0.733 2.241 1.419 - 3.539 0.001 1.338 0.987 - 1.814 0.061
   Haplo 0.577 0.298 - 1.117 0.103 1.948 1.069 - 3.552 0.029 1.017 0.657 - 1.574 0.941
KPS >80% 0.867 0.472 - 1.592 0.646 0.265 0.162 - 0.435 <10-5 0.486 0.331 - 0.715 <10-3
PBSC vs BM 0.998 0.635 - 1.568 0.992 1.325 0.825 - 2.128 0.244 1.117 0.804 - 1.553 0.509
Year of allo-HCT 0.985 0.935 - 1.037 0.556 0.943 0.889 - 1.001 0.054 0.968 0.93 - 1.007 0.104
Patient female 0.747 0.575 - 0.971 0.029 0.825 0.608 - 1.12 0.218 0.774 0.633 - 0.945 0.012
Donor female 0.909 0.687 - 1.203 0.505 1.027 0.745 - 1.415 0.869 0.95 0.768 - 1.174 0.634
in vivo TCD 1.028 0.761 - 1.389 0.859 1.047 0.746 - 1.468 0.792 1.042 0.826 - 1.315 0.727
centre 0.228 0.256 0.188
HR CI p HR CI p HR CI p
Age ≥50y
RIC vs MAC 0.915 0.713 - 1.175 0.489 1.04 0.832 - 1.299 0.733 0.921 0.648 - 1.307 0.644
Age (per 10 y) 1.265 1.056 - 1.516 0.011 1.017 0.865 - 1.196 0.840 0.927 0.717 - 1.197 0.559
Secondary AML 0.955 0.646 - 1.412 0.819 1.061 0.755 - 1.491 0.734 1.506 0.92 - 2.467 0.104
Time Diagnosis to allo-HCT (m) 0.988 0.98 - 0.996 0.002 0.993 0.986 - 1 0.037 1.004 0.996 - 1.012 0.357
Cytogenetics
Good risk group (reference data) 1 1 1
   Intermediate 1.202 0.903 - 1.6 0.206 1.192 0.934 - 1.521 0.159 1.031 0.685 - 1.552 0.883
   Adverse 1.607 1.042 - 2.479 0.032 1.31 0.879 - 1.954 0.185 0.833 0.403 - 1.724 0.623
Donor 
   MFD (reference data) 1 1 1
   VUD 10/10 1.183 0.909 - 1.54 0.210 1.137 0.906 - 1.426 0.267 1.68 1.118 - 2.525 0.013
   MMUD 9/10 1.511 1.098 - 2.081 0.011 1.516 1.146 - 2.004 0.004 2.685 1.692 - 4.26 <10-4
   Haplo 1.321 0.842 - 2.074 0.226 1.016 0.681 - 1.517 0.937 2.434 1.341 - 4.417 0.003
KPS >80% 0.437 0.297 - 0.645 <10-4 0.363 0.254 - 0.518 0.000 0.562 0.322 - 0.982 0.043
PBSC vs BM 1.167 0.827 - 1.649 0.379 1.172 0.863 - 1.593 0.309 1.331 0.809 - 2.191 0.260
Year of allo-HCT 0.968 0.927 - 1.01 0.133 0.97 0.936 - 1.007 0.108 0.986 0.932 - 1.043 0.622
Patient female 0.828 0.672 - 1.022 0.078 0.884 0.735 - 1.062 0.188 1.044 0.779 - 1.4 0.771
Donor female 1.008 0.808 - 1.259 0.941 1.065 0.88 - 1.29 0.516 0.919 0.669 - 1.261 0.599
in vivo TCD 1.082 0.853 - 1.371 0.516 0.764 0.617 - 0.945 0.013 0.93 0.659 - 1.312 0.679
centre 0.312 0.120 0.263
HR CI p HR CI p HR CI p
Age ≥50y
RIC vs MAC 0.729 0.428 - 1.242 0.245 1.377 1.027 - 1.845 0.032 1.352 0.869 - 2.102 0.181
Age (per 10 y) 0.71 0.469 - 1.075 0.106 0.863 0.698 - 1.067 0.173 0.79 0.571 - 1.093 0.155
Secondary AML 1.669 0.78 - 3.573 0.187 0.933 0.57 - 1.527 0.782 1.45 0.741 - 2.838 0.279
Time Diagnosis to allo-HCT (m) 1.008 0.997 - 1.02 0.143 0.996 0.988 - 1.003 0.249 1.005 0.995 - 1.015 0.316
Cytogenetics
Good risk group (reference data) 1 1 1
   Intermediate 1.082 0.574 - 2.043 0.807 1.161 0.843 - 1.599 0.359 1.064 0.667 - 1.7 0.794
   Adverse 0.357 0.079 - 1.614 0.181 1.583 0.917 - 2.732 0.099 1.071 0.435 - 2.639 0.881
Donor 
   MFD (reference data) 1 1 1
   VUD 10/10 1.293 0.669 - 2.5 0.445 0.983 0.738 - 1.311 0.909 1.388 0.892 - 2.159 0.146
   MMUD 9/10 4.167 2.125 - 8.173 <10-4 1.006 0.678 - 1.493 0.975 1.741 0.992 - 3.056 0.054
   Haplo 1.811 0.717 - 4.572 0.209 0.86 0.508 - 1.455 0.575 0.585 0.234 - 1.464 0.252
KPS >80% 0.338 0.152 - 0.748 0.007 0.758 0.432 - 1.33 0.333 0.66 0.261 - 1.671 0.381
PBSC vs BM 1.441 0.679 - 3.06 0.341 1.683 1.08 - 2.624 0.021 1.599 0.814 - 3.144 0.173
Year of allo-HCT 0.994 0.909 - 1.086 0.886 0.985 0.939 - 1.034 0.543 1.004 0.933 - 1.081 0.905
Patient female 1.114 0.704 - 1.762 0.644 1.137 0.886 - 1.458 0.313 1.08 0.743 - 1.571 0.686
Donor female 1.107 0.686 - 1.787 0.676 1.034 0.795 - 1.344 0.804 1.558 1.065 - 2.28 0.022
in vivo TCD 0.747 0.44 - 1.269 0.281 0.484 0.373 - 0.627 0.000 0.266 0.18 - 0.393 <10-5
centre 0.283 0.271 0.921
acute GVHD III-IV chronic GVHD ext. chronic GVHD
Relapse NRM LFS
OS GRFS acute GVHD II-IV
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